⌘K

Director/PDMR Shareholding

RNS Number : 6794G

Hikma Pharmaceuticals Plc

02 June 2026

Hikma Pharmaceuticals PLC - LTIP and EIP Vesting

LONDON, 2 June 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (Nasdaq Dubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMRs") have received shares as a result of the vesting of their conditional share awards which were granted on 30 May 2023 under the 2023 Long-Term Incentive Plan ("LTIP") and 2014 Executive Incentive Plan ("EIP") Element C.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities

Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Said Darwazah
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	LTIP Award: 91,812
		Nil	EIP Award, Element C: 19,761
d)	Aggregated information	Price(s): nil Volume(s): 111,573
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Mazen Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mazen Darwazah
2	Reason for the notification
a)	Position/status	Executive Vice Chairman and Deputy CEO, MENA
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	LTIP Award: 72,763
		Nil	EIP Award, Element C: 20,650
d)	Aggregated information	Price(s): nil Volume(s): 93,413
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Khalid Nabilsi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Khalid Nabilsi
2	Reason for the notification
a)	Position/status	Deputy CEO, North America and Europe
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	LTIP Award: 51,650
		Nil	EIP Award, Element C: 22,209
d)	Aggregated information	Price(s): nil Volume(s): 73,859
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Bassam Kanaan

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bassam Kanaan
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	LTIP Award: 52,640
		Nil	EIP Award, Element C: 20,982
d)	Aggregated information	Price(s): nil Volume(s): 73,622
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Hussein Arkhagha

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Hussein Arkhagha
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	LTIP Award: 28,631
		Nil	EIP Award, Element C: 12,406
d)	Aggregated information	Price(s): nil Volume(s): 41,037
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Susan Ringdal

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the LTIP and EIP.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	LTIP Award: 26,558
		Nil	EIP Award, Element C: 11,664
d)	Aggregated information	Price(s): nil Volume(s): 38,222
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083
b)	Nature of the transaction	All shares sold following the vesting of conditional awards under the LTIP and EIP.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.49	LTIP Award: 26,558
		£14.49	EIP Award, Element C: 11,664
d)	Aggregated information	Price(s): £14.49 Volume(s): 38,222 Total(s): £553,748.83
e)	Date of the transaction	1 June 2026
f)	Place of the transaction	London Stock Exchange (XLON)

Helen Middlemist
Group Company Secretary

+44 (0)20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBBGDLBSGDGLD

Director/PDMR Shareholding - Hikma Pharmaceuticals PLC | RNS | Ticker